目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.5 UNITS CONSIDERED
1.3.1 VALUE/CURRENCY UNIT
1.3.2 VOLUME UNIT
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 INSIGHTS FROM PRIMARY EXPERTS
2.2.2 TOP-DOWN APPROACH
2.3 LIMITATIONS
2.4 GROWTH RATE ASSUMPTIONS
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 STUDY ASSUMPTIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 MASS SPECTROMETRY
5.7.1.1.1 INTACT/TOP DOWN PROTEIN ANALYSIS
5.7.1.2 CHROMATOGRAPHY
5.7.1.3 BIOINFORMATICS TOOLS
5.7.1.4 PROTEIN MICROARRAYS
5.7.2 COMPLEMENTARY TECHNOLOGIES
5.7.2.1 GENOMICS
5.7.2.2 TRANSCRIPTOMICS
5.7.2.3 METABOLOMICS
5.7.3 ADJCENT TECHNOLOGY
5.7.3.1 SINGLE-CELL PROTEOMICS
5.8 IMPACT OF GENERATIVE-AI ON PROTEOMICS MARKET
5.9 PATENT ANALYSIS
5.1 TRADE DATA ANALYSIS
5.10.1 IMPORT SCENERIO
5.10.2 EXPORT SCENERIO
5.11 KEY CONFERENCES & EVENTS 2024-2025
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY SCENERIO
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES’ ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTE
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSTITY OF COMPETITION RIVALRY
5.14 INVESTMENT AND FUNDING SCENARIO
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA

6 PROTEOMICS INSTRUMENTATION MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
6.2 SPECTROSCOPY
6.2.1 MASS SPECTROMETRY
6.2.2 NMR SPECTROSCOPY
6.2.3 CD SPECTROSCOPY
6.3 CHROMATOGRAPHY
6.3.1 HPLC
6.3.2 ION CHROMATOGRAPHY
6.3.3 AFFINITY CHROMATOGRAPHY
6.3.4 SUPERCRITICAL FLUID CHROMATOGRAPHY
6.4 ELECTROPHORESIS
6.4.1 GEL ELECTROPHORESIS
6.4.2 CAPILLARY ELECTROPHORESIS
6.5 PROTEIN MICROARRAYS
6.5.1 BIOCHIPS
6.5.1.1 Lab-on-chips
6.3.1.2 Protein Chips
6.5.2 MICROARRAY INSTRUMENTS
6.5.2.1 Integrated Systems
6.5.2.2 Microarray Scanners
6.5.2.3 Arrayers
6.6 X-RAY CRYSTALLOGRAPHY
6.7 SURFACE PLASMON RESONANCE
6.8 PROTEIN FRACTIONATION
6.9 OTHER TECHNOLOGIES
Note1: Tentative segmentation, subject to minor revision as research progresses.
Note2: Other Technologies segment includes blotting, ELISA, and Edman sequencing, etc.

7 PROTEOMICS REAGENTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 IMMUNOASSAY REAGENTS
7.3 SPECTROSCOPY REAGENTS
7.4 CHROMATOGRAPHY REAGENTS
7.5 PROTEIN MICROARRAY REAGENTS
7.6 X-RAY CRYSTALLOGRAPHY REAGENTS
7.7 ELECTROPHORESIS REAGENTS
7.8 PROTEIN FRACTIONATION REAGENTS
7.9 OTHER REAGENTS
Note 3: Tentative segmentation, subject to minor revision as research progresses.
Note 4: Other reagents segment includes reagents for Edman sequencing, enzymes, and cross-linking agents.

8 PROTEOMICS SERVICES MARKET, BY TYPE
8.1 INTRODUCTION
8.2 CORE PROTEOMICS SERVICES
8.2.1 PROTEIN IDENTIFICATION SERVICES
8.2.2 PROTEIN CHARACTERIZATION SERVICES
8.2.3 QUANTITATIVE PROTEOMICS SERVICES
8.2.4 PROTEIN PURIFICATION SERVICES
8.2.5 PROTEIN SEPARATION SERVICES
8.2.6 PROTEIN SEQUENCING SERVICES
8.2.7 CUSTOM ASSAY SERVICES
8.2.8 BIOINFORMATICS SERVICES

9 PROTEOMICS SOFTWARE MARKET, BY TYPE
9.2 BIOINFORMATICS TOOLS
9.3 BIOINFORMATICS DATABASES

10 PROTEOMICS MARKET, BY APPLICATION
10.1 INTRODUCTION
10.1 CLINICAL DIAGNOSTICS
10.2.1 CANCER
10.2.2 INFECTIOUS DISEASES
10.2.3 DIABETES
10.2.4 NEUROLOGICAL DISORDERS
10.2.5 AUTOIMMUNE DISEASES
10.2.6 CARDIOVASCULAR DISEASES
10.2.7 OTHER CLINICAL DIAGNOSTIC APPLICATIONS
Note 5: Other clinical diagnostic applications segment includes dermatology, blood disorders, digestive diseases, respiratory diseases, postmenopausal osteoporosis, nephrology, and rare diseases.
10.3 DRUG DISCOVERY & DEVELOPMENT
10.3.1 TARGET DISCOVERY
10.3.2 LEAD IDENTIFICATION
10.3.3 LEAD OPTIMIZATION
10.3.4 PRECLINICAL STUDIES
10.4 OTHER APPLICATIONS
Note 6: Other applications segment includes protein mining (identification of proteins), protein-expression profile (identification of proteins in a state of the organism), and protein-network mapping (protein interactions in living systems and mapping of protein modifications).

11 PROTEOMICS MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITALS
11.3 CLINICAL LABORATORIES
11.4 BIPHARMACEUTICAL COMPANIES
11.5 ACADEMIC & RESEARCH INSTITUTES
11.6 OTHER END USERS
Note 7: Other end users segment includes CROs, forensic laboratories, CMOs, and CDMOs.

12 PROTEOMICS MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.3 CANADA
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.3 UK
12.3.4 FRANCE
12.3.5 ITALY
12.3.6 SWITZERLAND
12.3.7 SPAIN
12.3.8 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.3 JAPAN
12.4.4 INDIA
12.4.5 AUSTRALIA
12.4.6 SOUTH KOREA
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.3 MEXICO
12.5.4 REST OF LATIN AMERICA
12.6
12.5.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.6.2 GCC COUNTRIES
12.6.2.1 SAUDI ARABIA (KSA)
12.6.2.2 UNITED ARAB EMIRATES (UAE)
12.6.2.3 REST OF GCC COUNTRIES
12.6.3 REST OF MIDDLE EAST
12.7
12.7.1 MACROECONOMIC OUTLOOK FOR AFRICA
Note 8: Rest of Europe includes Russia, Switzerland, Portugal, Poland, Netherlands, Finland, Belgium, Austria, Hungary, Iceland, Ireland, Norway, and Luxembourg, among others
Note 9: Rest of Asia Pacific Includes Bangladesh, Bhutan, Nepal, Sri Lanka, Philippines, Singapore, Vietnam, Thailand, Taiwan, Cambodia, and Indonesia among others
Note 10: Rest of Latin America Includes Colombia, Ecuador, Peru, Uruguay, Cuba and Chile
Note 11: Rest of GCC includes Bahrain, Kuwait, Qatar and Oman
Note 13: Rest of Middle East Includes Iran, Iraq, Israel, Jordan, Qatar, Yemen, and other countries.

13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATERGIES/RIGHT TO WIN
13.3 REVENUE ANALYSIS, 2021-2023
13.4 MARKET SHARE ANALYSIS, 2023
13.5 BRAND/PRODUCT COMPARATIVE ANALYSIS
13.5.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY TECHNOLOGY
13.6 COMPANY EVALUATION MATRIX:KEY PLAYERS, 2023
13.6.1 STARS
13.6.2 EMERGING LEADERS
13.6.3 PERVASIVE PLAYERS
13.6.4 PARTICIPANTS
13.6.5 COMPANY FOOTPRINT:KEY PLAYERS, 2023
13.6.5.1 COMPANY FOOTPRINT
13.6.5.2 REGION FOOTPRINT
13.6.5.3 INSTRUMENTATION TECHNOLOGY FOOTPRINT
13.6.5.4 REAGENT FOOTPRINT
13.6.5.4 SERVICE FOOTPRINT
13.6.5.5 SOFTWARE FOOTPRINT
13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
13.7.1 PROGRESSIVE COMPANIES
13.7.2 RESPONSIVE COMPANIES
13.7.3 DYNAMIC COMPANIES
13.7.4 STARTING BLOCKS
13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
13.7.5.1 PROTEOMICS MARKET: KEY STARTUPS/SMES
13.7.5.2 PROTEOMICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
13.8 VALUATION AND FINANCIAL METRICS OF KEY PROTEOMICS MARKET PLAYERS
13.9 COMPETITIVE SCENARIO AND TRENDS
13.9.1 PRODUCT LAUNCHES & APPROVALS
13.9.2 DEALS
13.9.3 OTHER DEVELOPMENTS

14 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, Mnm View)*
14.1 KEY PLAYERS
14.1.1 THERMO FISHER SCIENTIFIC INC.
14.1.2 AGILENT TECHNOLOGIES, INC.
14.1.3 MERCK KGAA
14.1.4 DANAHER
14.1.5 WATERS CORPORATION
14.1.6 BIO-RAD LABORATORIES, INC.
14.1.7 BRUKER CORPORATION
14.1.8 REVITTY
14.1.9 SHIMADZU CORPORATION
14.1.10 ILLUMINA, INC.
14.1.11 PROMEGA CORPORATION
14.1.12 EUROFINS SCIENTIFIC
14.1.13 QIAGEN
14.1.14 CHARLES RIVER LABORATORIES
14.1.15 PROTAGENE
13.2 OTHER PLAYERS
13.2.1 CREATIVE PROTEOMICS
13.2.2 HORIBA
13.2.3 SENGENICS CORPORATION LLC.
13.2.4 LABVANTAGE - BIOMAX GMBH
13.2.5 CELL SIGNALING TECHNOLOGY, INC.
13.2.6 FIOS GENOMICS
13.2.7 AZENTA LIFE SCIENCES
13.2.8 MEDGENOME
13.2.9 BIOGNOSYS AG
13.2.10 MACROGEN INC.
*Business overview, products offered, recent developments, SWOT analysis, MNM view might not be captured in the case of unlisted companies.
Note 13: Tentative list of companies, subject to minor revision as research progresses.

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS